In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Leap Therapeutics (LPTX – Research Report), with a price target of $4.00. The company’s shares closed last Friday at $1.31, close to its 52-week low of $0.92.
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -1.2% and a 31.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Janux Therapeutics Inc.
Currently, the analyst consensus on Leap Therapeutics is a Moderate Buy with an average price target of $5.00, implying a 385.4% upside from current levels. In a report issued on May 13, Mizuho Securities also maintained a Buy rating on the stock with a $6.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Leap Therapeutics’ market cap is currently $115.7M and has a P/E ratio of -2.57.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Read More on LPTX:
- Crinetics Pharmaceuticals (CRNX) Receives a Buy from H.C. Wainwright
- H.C. Wainwright Thinks Yield10 Bioscience’s Stock is Going to Recover
- H.C. Wainwright Thinks Riot Blockchain’s Stock is Going to Recover
- H.C. Wainwright Thinks Flux Power Holdings’ Stock is Going to Recover
- H.C. Wainwright Keeps Their Buy Rating on Vor Biopharma (VOR)
